Stock listing
Hanover:5VA Vaxcyte, Inc. Aktie
German listing (Hanover) of Vaxcyte, Inc. · home listing NASDAQ:PCVX
Follow Vaxcyte, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:PCVX
$67.55 USD +0.75 (+1.1%)
Close on Oct 14, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:PCVX
- Ticker
- Hanover:5VA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Hanover
- Currency
- EUR
What changed lately
Latest news release · Oct 9, 2026
Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes
Latest earnings call · Feb 24, 2026
Vaxcyte (NASDAQ:PCVX) Q4 2025 Earnings Call
Replay and transcript
Latest deck · Oct 5, 2026
Technical Presentation (October 2026)
Technical · 34 slides
Calls
Replays
Vaxcyte (NASDAQ:PCVX) Q4 2025 Earnings Call
Tue, Feb 24, 2026 · 4:30 PM ET
Watch TranscriptVaxcyte (NASDAQ:PCVX) Q4 2024 Earnings Call
Tue, Feb 25, 2025 · 1:30 PM ET
Watch TranscriptVaxcyte (NASDAQ:PCVX) Q4 2023 Earnings Call
Tue, Feb 27, 2024 · 4:30 PM ET
Watch Transcript
Latest news
Financings
Public offering of common stock and pre-funded warrants
Oct 9, 2026
Closed: US$500M raised · US$64 a share · Jefferies +7
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), BofA Securities (co-lead), Evercore ISI (co-lead), Goldman Sachs & Co. LLC (co-lead), Guggenheim Securities (co-lead), Mizuho, BTIG
Use of proceeds: VAX-31 adult and pediatric clinical development, manufacturing scale-up, US launch preparation, early pipeline R&D and general corporate purposes
Announced Oct 5, 2026 · Update Oct 7, 2026 · Closed Oct 9, 2026
1.50% convertible senior notes due 2032
Oct 9, 2026
Closed: US$575M raised · Jefferies +8
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), BofA Securities (co-lead), Goldman Sachs & Co. LLC (co-lead), Evercore ISI (co-lead), Guggenheim Securities, Mizuho, Needham & Company, J. Wood Capital Advisors
Use of proceeds: VAX-31 adult and pediatric clinical development, manufacturing scale-up, US launch preparation, early pipeline R&D and general corporate purposes
Announced Oct 5, 2026 · Update Oct 7, 2026 · Closed Oct 9, 2026
Decks
Technical Presentation (October 2026)
Technical · 34 slides · Oct 5, 2026
Technical Presentation (October 2026)
Technical · 35 slides · Oct 5, 2026
Investor Presentation (September 2026)
Investor deck · 80 slides · Sep 3, 2026
Q4 2025 Earnings Presentation
Earnings · 68 slides · Feb 24, 2026
Vaxcyte, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 25 in the last 12 months · 127 in all · newest Oct 9, 2026 · oldest 2020
- Calls
- 5 calls with a replay · 5 with a transcript · latest Feb 24, 2026
- Decks
- 9 decks · latest Oct 5, 2026
Where Vaxcyte, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PCVX · Home listing | NASDAQ | United States | USD |
| gettex:5VA | gettex | Germany | EUR |
| LS Exchange:A2P6R6 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2P6R6 | Lang & Schwarz | Germany | EUR |
| Milan:1PCVX | Milan | Italy | EUR |
| BOATS:PCVX | BOATS | United States | USD |
| Frankfurt:5VA | Frankfurt | Germany | EUR |
| BX Swiss:PCVX | BX Swiss | Switzerland | CHF |
| Dusseldorf:5VA | Dusseldorf | Germany | EUR |
| Hamburg:5VA | Hamburg | Germany | EUR |
| Munich:5VA | Munich | Germany | EUR |
| Stuttgart:5VA | Stuttgart | Germany | EUR |
| Tradegate:5VA | Tradegate | Germany | EUR |
| Hanover:5VA · This page | Hanover | Germany | EUR |
| Xetra:5VA | Xetra | Germany | EUR |
Log in to ask 6ix AI your own questions about Vaxcyte, Inc.